RecruitingNCT06486350

IL-6: A Marker for AML Chemo Sensitivity

Bone Marrow Supernatant IL-6 as a Predictor of Chemotherapy Sensitivity in AML Patients

Sponsor

Fujian Medical University Union Hospital

Enrollment

72 participants

Start Date

Oct 1, 2023

Study Type

OBSERVATIONAL

Conditions

AML, Adult

Summary

Acute myeloid leukemia (AML) is a clonal malignancy that arises from the primitive hematopoietic cells within the hematopoietic system. According to SEER cancer statistics, the 5-year survival rate for AML patients stands at a concerning 30%. Despite therapeutic advancements, the development of chemotherapy resistance and the risk of disease relapse pose significant barriers to curative outcomes. Evidence has linked elevated interleukin-6 (IL-6) levels in plasma and bone marrow to a poorer prognosis in AML, with IL-6 potentially fostering chemotherapy resistance through the enhancement of fatty acid uptake and the induction of stromal-like morphological changes in AML cells. However, the role of IL-6 as a potential biomarker for monitoring chemotherapy sensitivity in AML has not been fully elucidated. This study seeks to investigate the correlation between IL-6 levels in bone marrow supernatant and the sensitivity to chemotherapy, offering a clinical perspective that could pave the way for improved prognostic markers and personalized treatment strategies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether a protein in the blood called IL-6 can predict how well a patient with acute myeloid leukemia (AML, a fast-growing blood cancer) will respond to chemotherapy — potentially helping doctors choose the best treatment approach. **You may be eligible if...** - You are an adult with a new diagnosis of AML (not the APL subtype) - This is your first episode of AML and you have not yet received chemotherapy - You have adequate organ function and overall health - You are accompanied by a family member and willing to sign an informed consent form **You may NOT be eligible if...** - You have another active cancer requiring treatment - You have infectious diseases including HIV, hepatitis, or SARS - You had major surgery within the last 21 days - You have a poor performance status (PS score above 3) - You have severe liver, kidney, or psychiatric conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.